A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

G. Richardson, Paul; Barlogie, Bart; R. Berenson, James; Singhal, Seema; Jagannath, Sundar; Irwin, David; Vincent Rajkumar, S.; Srkalović, Gordan; Alsina, Melissa; Alexanian, Raymond; S. Siegel, David; Z. Orlowski, Robert; J. Kuter, David; Limentani, Steven; J. Lee, Stephanie; Hideshima, Teru; Esseltine, Dixie‐Lee; Kauffman, Michael; Adams, Julian; P. Schenkein, David; C. Anderson, Kenneth

doi:10.1056/nejmoa030288

Public

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Published in New England Journal of Medicine • Jun 25, 2003

Authors:

Paul G. Richardson

Bart Barlogie

James R. Berenson

Abstract

BACKGROUND: Bortezomib, a boronic acid dipeptide, is a novel proteasome inhibitor that has been shown in preclinical and phase 1 studies to have antimyeloma activity. METHODS: In this multicenter, open-label, nonrandomized, phase 2 trial, we enrolled 202 patients with relapsed myeloma that was refra...

Subject

Medicine

Bortezomib

Multiple myeloma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!